Lv42
800 积分 2024-07-09 加入
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
1天前
待确认
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
1天前
待确认
Dual-payload ADCs move into first oncology clinical trials
2个月前
已完结
The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer
4个月前
已完结
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer
4个月前
已完结
[Expert consensus on the management practice of CD19 CAR-T cell therapy for B-cell lymphoma in China (2025 edition)]
4个月前
已完结
Five‐Year Follow‐Up: Tandem CD19 / CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non‐Hodgkin Lymphoma
4个月前
已完结
Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT)
5个月前
已完结
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
6个月前
已完结
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
7个月前
已完结
皖公网安备34019202002308
